MedTrace Logo

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

NCT04208958 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-10-27

Study results available
· View outcomes & findings →

Summary

This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer

Conditions

Interventions

BIOLOGICAL

VE800

VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.

DRUG

Nivolumab

Nivolumab is an approved medication that blocks antibodies for certain types of cancer.

DRUG

Vancomycin Oral Capsule

Vancomycin is an antibiotic used to treat or prevent infection.

Sponsors & Collaborators

Principal Investigators

  • Judy Wang, MD · SCRI - Florida Cancer Specialists - Sarasota Cattlemen Office (Coordinating Investigator)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-23
Primary Completion
2021-08-26
Completion
2023-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04208958 on ClinicalTrials.gov